The 13-Fold Cancer Gap: What African Gut Health Can Teach Us About Bowel Cancer Prevention
By Bamidele Abudu, GPhC-Registered Pharmacist | Morlongevity
Here is a number that should stop you in your tracks.
Rural Africans develop bowel cancer at a rate of fewer than 5 per 100,000 people. African Americans develop it at a rate of 65 per 100,000.
Same ancestral origin. Radically different outcomes. A 13-fold difference in one of the most preventable cancers we know.
That gap is not explained by genetics. It is not explained by healthcare access alone. And it is certainly not explained by bad luck.
It is explained, in large part, by what is living inside the gut
And what is feeding it?
This piece unpacks one of the most compelling datasets in modern cancer science: the growing body of research linking gut microbiome health to the risk of bowel cancer. As a pharmacist, I want to give you the science clearly and honestly, not to alarm you, but to show you exactly where your agency lies.
Bowel Cancer in the UK: The Numbers You Need to Know
Let us start with context. Bowel cancer — also called colorectal cancer (CRC) — is the fourth most common cancer in the UK, with approximately 46,500 new diagnoses every year. It causes around 17,700 deaths annually, making it the second leading cause of cancer death in this country.
The survival statistics are stark: catch it at Stage 1 and you have roughly a 90% chance of surviving five years.
By Stage 4, that drops to around 10%. This is not a disease where late detection is a minor inconvenience. It can be a death sentence.
What should concern us further is the trend in younger adults. A 2025 population-based cohort study tracking UK data from 2000 to 2021 found that early-onset CRC, diagnosed in people under 50, rose continuously throughout the study period, from 8.33 to 19.07 per 100,000 person-years. Bowel cancer is no longer just a condition of old age.
And yet Cancer Research UK’s own data shows that up to 54% of bowel cancer cases are preventable through lifestyle modification. Science is increasingly pointing to the gut microbiome as the mechanism through which many of those lifestyle choices either protect us or expose us to risk.
The African Data That Changes Everything
In the late 2000s, researchers began investigating the extraordinary difference in bowel cancer rates between rural Black Africans and African Americans. The two groups share deep ancestral connections, but their cancer rates could not be more different.
The answer, when it emerged, was clarifying and humbling in equal measure.
Rural Africans consuming traditional high-fibre, plant-rich diets showed fecal bile acid levels two to three times lower than African Americans eating a typical Western diet.
Their gut microbiome was producing dramatically different metabolic outputs, particularly around the handling of bile acids, the digestive compounds that, when metabolised incorrectly by harmful gut bacteria, can damage the colon lining and drive cancer development.
The rural African gut was, in effect, doing what a healthy gut is designed to do: fermenting plant fibre, keeping inflammation suppressed, and metabolising bile acids in a way that protected rather than harmed the colon.
This is not a story about race. It is a story about what we feed the trillions of bacteria living inside us, and what those bacteria do in return.
What the Gut Microbiome Actually Does
Your gut is home to approximately 38 trillion microorganisms, including bacteria, fungi, viruses, and archaea, collectively known as the microbiome. These are not passive residents. They are metabolically active partners that digest food your body cannot process, train your immune system, regulate inflammation, produce compounds that feed your colon cells, and communicate directly with your brain.
For cancer prevention, three of their functions matter most.
1. Short-Chain Fatty Acid Production
When beneficial gut bacteria, particularly species like Faecalibacterium prausnitzii, Bifidobacterium, and Roseburia, ferment dietary fibre, they produce compounds called short-chain fatty acids (SCFAs): butyrate, propionate, and acetate.
Butyrate deserves special mention. It is the primary fuel source for the cells lining your colon, supplying roughly 70% of their energy.
But it does something far more remarkable than simply feeding cells. Butyrate acts as a histone deacetylase (HDAC) inhibitor, the same class of compounds used in cancer therapy, meaning it can switch off genes that promote tumour growth and switch on genes that trigger cancer cell death.
A 2024 review in the International Journal of Oncology documented what researchers call the “Warburg effect paradox”: cancer cells switch to a different energy pathway (aerobic glycolysis), which causes butyrate to accumulate to levels that trigger programmed cell death in tumour cells.
Normal healthy cells simply metabolise butyrate as fuel and thrive. It is, in essence, a targeted molecular mechanism that harms cancer cells while protecting healthy ones.
Less fibre means less fermentation. Less fermentation means less butyrate. Less butyrate means the colon is running without its most important protective compound.
2. Immune System Training
Approximately 70% of your entire immune system resides in or around the gut, in a network called the gut-associated lymphoid tissue (GALT). The bacteria living in your gut are not just passive inhabitants of this immune territory; they actively train it.
A landmark 2019 study published in Nature by Tanoue and colleagues isolated a consortium of eleven bacterial strains from healthy human faeces that were capable of inducing a potent population of immune cells called interferon-γ-producing CD8+ T cells.
These are cytotoxic “killer” T cells, the cells responsible for identifying and destroying abnormal and cancerous cells before they establish themselves as tumours.
The key finding was that this immune training was dependent on the presence of specific bacterial strains. Change the microbiome, and you change the immune army your body has available to run cancer surveillance.
3. Bile Acid Management
Every time you eat fat, your liver releases bile acids to help digest it. Certain gut bacteria, particularly harmful species such as Clostridium, convert primary bile acids into secondary bile acids that are toxic to colon cells and drive inflammation.
The more harmful bacteria dominate the gut, the more secondary bile acids accumulate, and the greater the colon’s exposure to carcinogenic compounds.
A 2018 study in Science by Ma and colleagues demonstrated that gut bacteria use bile acids as signaling molecules to regulate the liver’s immune response, including the activity of NKT cells, a type of immune cell that plays a direct role in liver cancer surveillance.
The microbial management of bile acids is not a peripheral detail; it is a central mechanism connecting diet, gut health, and cancer risk.
The Bacteria That Protect You — and the Ones That Don’t
Modern microbiome research has identified specific bacterial species consistently associated with higher or lower cancer risk.
On the protective side, three species have accumulated particularly strong evidence:
Akkermansia muciniphila lives in the mucus layer of the gut and maintains intestinal barrier integrity.
A landmark study in Science by Routy et al. (2018), now one of the most cited papers in cancer immunology, found that patients whose microbiomes contained Akkermansia responded significantly better to cancer immunotherapy, with higher response rates and longer survival.
Akkermansia appears to enhance the recruitment of immune cells into tumours and amplify the cancer-killing capacity of the immune system.
Faecalibacterium prausnitzii is the most abundant butyrate-producing bacterium in the healthy human colon, representing over 5% of total gut bacteria in healthy adults.
It is consistently depleted in patients with colorectal cancer, inflammatory bowel disease, and other inflammatory conditions. Its supernatant (the compounds it secretes) directly blocks the NF-κB inflammatory pathway and suppresses pro-inflammatory cytokines. Think of it as the gut’s natural anti-inflammatory drug.
Bifidobacterium species reduce the activity of an enzyme called beta-glucuronidase, which deconjugates oestrogens in the bowel, a process relevant not only to bowel cancer but to hormone-dependent breast cancer risk.
A 2023 Mendelian randomisation study in BMC Genomics, a design that tests causation rather than just correlation, identified Lactobacillales (the broader order including both Lactobacillus and Bifidobacterium) as causally associated with reduced total breast cancer risk.
On the harmful side, Fusobacterium nucleatum has emerged as the most consistent cancer-associated pathogen.
A 2021 meta-analysis in the European Medical Journal synthesising 31 studies found F. nucleatum enriched by more than fourfold in CRC patients compared to healthy controls. It is now considered a potential diagnostic biomarker and is being investigated as a target for microbiome-based cancer prevention strategies.
What the Clinical Trial Data Shows
It is one thing to observe associations. It is another to demonstrate that intervening in gut health changes cancer outcomes. The clinical trial data are now starting to catch up with the mechanistic research.
A clinical trial known as the SYNCAN study, the first placebo-controlled randomised trial in this space, found that a combination of prebiotic fibre (oligofructose-enriched inulin) with Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12 produced a 20% reduction in colorectal cell proliferation in patients who had previously had polyps or colorectal cancer. Reduced cell proliferation is a direct marker of reduced cancer risk.
A 2023 meta-analysis of nine randomised controlled trials confirmed that probiotic supplementation significantly reduced adenoma incidence (the precancerous growths that precede most bowel cancers) in high-risk populations.
Perhaps the most striking recent data comes from the emerging field of faecal microbiota transplantation (FMT). The TACITO Phase II Randomised Trial, published in Nature Medicine in 2025, was the first randomised trial in the world to test FMT combined with immunotherapy against placebo in metastatic kidney cancer.
The results were remarkable: median progression-free survival was 24 months in the FMT group versus 9 months in the placebo group. In related trials, 80% of lung cancer patients and 75% of melanoma patients receiving FMT before standard immunotherapy showed tumour shrinkage.
These are not alternative medicine claims. These are Phase II randomised controlled trials published in Nature Medicine.
The Fibre Gap Is the Cancer Gap
Across all of this research, one factor appears with striking consistency: dietary fibre.
Fibre is not just roughage that keeps you regular. It is the primary substrate that feeds the bacteria responsible for butyrate production, SCFA generation, and maintaining a healthy, anti-inflammatory microbial ecosystem.
A landmark 2021 study published in Science by Spencer and colleagues followed 128 melanoma patients receiving immune checkpoint therapy and found that every 5g per day increase in dietary fibre reduced the risk of disease progression or death by 30%. Patients with sufficient fibre intake were five times more likely to respond to immunotherapy.
The average UK adult consumes approximately 18 grams of dietary fibre per day. The recommended intake is 30 grams. The gut health cancer gap is, in significant part, a fibre gap.
One Important Nuance on Probiotics
The research finds that every pharmacist should communicate clearly.
The Spencer et al. study mentioned above found that patients who took commercial probiotic supplements alongside their cancer treatment had worse outcomes, reduced gut microbiome diversity, lower levels of cytotoxic T cells in tumours, and poorer immunotherapy response.
This is not an argument against probiotics in general, but it is a powerful reminder that not all probiotics are equal, that strain selection matters enormously, and that food-first approaches to building microbial diversity are likely more reliable for most people than reaching for an off-the-shelf supplement.
This nuance is part of what makes pharmacist-led guidance in this space so valuable.
What This Means for You Right Now
The evidence points clearly to a set of practical, evidence-based steps that can meaningfully shift cancer risk over the long term:
Increase dietary fibre progressively toward 30g per day, prioritising a diversity of plant foods. Research consistently shows that 30 different plant species per week produces a meaningfully more diverse and protective microbiome than a narrow diet.
Protect and feed your butyrate-producing bacteria — F. prausnitzii, Roseburia, Eubacterium rectale — through resistant starches (cooled cooked potatoes, legumes, green bananas), whole grains, and cruciferous vegetables.
Minimise processed meat. Cancer Research UK identifies a significant association between processed meat intake and bowel cancer risk — the mechanism runs through the gut microbiome.
Be strategic, not reflexive, about probiotics. Seek strains with clinical evidence rather than generic multi-strain products.
Understand that your gut health is cumulative. What you eat consistently over months and years shapes the microbial ecosystem that either runs cancer surveillance or fails to.
The 13-fold difference between rural African and African American bowel cancer rates is not a fixed biological fact. It is a lifestyle-driven outcome. And lifestyle can be changed.
Take the Next Step
At Morlongevity, everything we do is grounded in the same evidence base that informs this article.
Our Gut Optimisation Guide translates this research into a practical, day-by-day protocol, including dietary strategies, the specific bacterial strains with the strongest clinical evidence, and how our Gateway Trio (NovaBiome, GutGlow Greens, and NovaFlow Fibre) supports each mechanism covered here.
Download the free Gut Optimisation Guide and start building the microbiome that works in your favour.
Download the Gut Optimisation Guide →Â
Dele Abudu is a GPhC-registered pharmacist and founder of Morlongevity. The information in this article is for educational purposes and does not constitute medical advice. Please consult your GP or healthcare provider before making changes to your supplement regimen.
